This government file, titled "UF BPA NDC Price List for the November 2025 DoD P&T Meeting" and "UF ADP Appendix for the November 2025 DoD P&T Meeting," outlines the Department of Defense's (DOD) Uniform Formulary and Additional Discount Program for "HEMATOLOGICAL AGENTS" specifically in the "PLATELETS" subclass. Quotes for these agents are due by October 27, 2025, in anticipation of the P&T Committee Meeting on November 5-6, 2025. The document details requirements for submitting quotes for both Uniform Formulary and Non-Formulary drugs, as well as for TRICARE Retail Refund for Tier 2 and Tier 3 agents. It emphasizes that prior authorization may apply, and the P&T Committee can recommend preferential status for non-generic agents or even exclude certain agents from the TRICARE pharmacy benefit. Manufacturers are reminded to submit fully executed signature pages with their quotes, and pricing will be consistent across package sizes within a given dispensing venue. The Additional Discount Program also details the calculation of total retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for products without an FCP, such as diabetic supplies.

The document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Program for Breast Cancer Agents, specifically Estrogen Receptor Antagonists. The P&T Committee Meeting is scheduled for November 5-6, 2025, with quotes due by October 27, 2025. Manufacturers are invited to submit quotes for both formulary and non-formulary drugs, as well as for TRICARE Retail Refunds across Tier 2 and Tier 3 categories. The document emphasizes that agents will be reviewed per 32 CFR 199.21(g)(5), with potential for Prior Authorization, special reimbursement methods, preferential status, or even complete exclusion from the TRICARE pharmacy benefit program. Manufacturers must submit fully executed signature pages along with their quote information. The pricing for the Blanket Purchase Agreement Appendix will be consistent across all package sizes for a given dosage form and strength, while the Additional Discount Program details the calculation of retail refunds based on non-FAMP and Federal Ceiling Price, or WAC for products without FCP. The document repeatedly lists specific NDC numbers for formulary, non-formulary, Tier 2, and Tier 3 scenarios, all marked as 'NO QUOTE' or awaiting pricing information, indicating a request for proposals from manufacturers for these listed items.

This document is an amendment to Solicitation HT9402-25-Q-9404 from the Defense Health Agency, dated October 22, 2025. The purpose of this amendment is to update the classification of the drug Inluriyo. Previously categorized as "Oncological Agents," Inluriyo has been reclassified as "Breast Cancer Agents – Estrogen Receptor Antagonist." This change also results in updated price list and condition sets for the drug. All other terms and conditions of the original solicitation remain unchanged. The amendment is officially signed by Marsha L. Petersen, the Contracting Officer.

The Department of Defense (DoD) has finalized a rule clarifying the formulary placement process for newly approved innovator drugs within the TRICARE Pharmacy Benefits Program. Effective August 26, 2015, the Pharmacy and Therapeutics (P&T) Committee has up to 120 days to recommend tier placement for FDA-approved drugs, including new molecular entities, active ingredients, dosage forms, and combinations. Drugs approved on or after this date will have a pending status and be treated as non-formulary. The DHA Director holds final approval authority for P&T Committee recommendations. Cost-effectiveness is a key evaluation factor, with the government soliciting quotes for newly approved drugs. Drugs are assigned to Tier 1, 2, 3, or 4/Not Covered based on clinical and cost-effectiveness data. Innovator drugs are generally Tier 3 and require medical necessity for availability at Military Treatment Facilities (MTFs) or a lower copay at retail pharmacies. The DoD will not accept clinical presentations from manufacturers due to the volume of new drugs.

The "Price Appendix FAQ" outlines instructions for completing price submission spreadsheets for government contracts, covering three main sections: BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). For each section, it details which cells to fill (yellow cells), auto-calculation features, and how to indicate non-submission for a quote by highlighting cells red. The document specifies that only relevant NDC tables need to be completed (up to 10 provided), with options to request more tables for additional NDCs. It emphasizes reading "Formulary Notes" for P&T committee decision-making and provides contact information for questions or concerns. The WAC Discount section specifically notes its use for products without a Federal Ceiling Price, like diabetic supplies. The overall purpose is to guide vendors through the accurate and compliant submission of pricing information for pharmaceutical and medical supply contracts.

The Department of Defense (DOD) is seeking Blanket Purchase Agreements (BPAs) for newly approved antibiotic drugs, as outlined in the Uniform Formulary and Additional Discount Program appendices. Quotes are due by October 27, 2025, for review at the P&T Committee Meeting on November 5-6, 2025. These documents specify requirements for drug pricing, including "NO QUOTE" options for certain National Drug Codes (NDCs) under both Uniform Formulary and Non-Formulary scenarios in Military Treatment Facilities and Mail Order. The Additional Discount Program details TRICARE Retail Refund mechanisms for Tier 2 and Tier 3 drugs, including calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for products without FCPs. Manufacturers must submit executed signature pages with their quotes, acknowledging that the P&T Committee may recommend prior authorization, special reimbursement methods, preferential status, or even exclusion from the TRICARE pharmacy benefit program. Step therapy may apply to agents for which no quote is submitted or selected.

The document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Programs for Migraine Agents, with quotes due by October 27, 2025, for a P&T Committee Meeting on November 5-6, 2025. It details requirements for Blanket Purchase Agreements for newly approved drugs, including NDC numbers, drug names, strengths, dosage forms, package sizes, condition sets, and pricing scenarios for both Uniform Formulary and Non-Formulary agents. Manufacturers are instructed to submit fully executed signature pages with their quotes. The document also covers TRICARE Retail Refund conditions for Tier 2 and Tier 3 drugs, specifying calculations based on non-FAMP and Federal Ceiling Price (FCP), or Wholesale Acquisition Cost (WAC) for products without FCP. Agents will be reviewed per 32 CFR 199.21(g)(5), with potential for Prior Authorization, special reimbursement methods, preferential status, or exclusion from the TRICARE pharmacy benefit program. Non-submitted or non-selected agents may be designated as non-step preferred (after-step).

The document outlines the Department of Defense (DOD) Uniform Formulary for CORTICOSTEROIDS-IMMUNE MODULATORS, specifically HEREDITARY ANGIOEDEMA AGENTS, with a P&T Committee Meeting scheduled for November 5-6, 2025, and quotes due by October 27, 2025. It details requirements for Blanket Purchase Agreements and Additional Discount Programs, emphasizing the submission of quotes for Uniform and Non-Formulary drugs, as well as Tier 2 and Tier 3 TRICARE Retail Refund scenarios. The P&T Committee will review these agents for potential prior authorization, special reimbursement methods, preferential status (Tier 1), or exclusion from the TRICARE pharmacy benefit program. Manufacturers are reminded to submit fully executed signature pages with their quote information.

The Department of Defense (DOD) Uniform Formulary Class for DIURETICS is undergoing review, with quotes due by October 27, 2025, for consideration at the P&T Committee Meeting on November 5-6, 2025. This request for quotation (RFQ) includes both Blanket Purchase Agreement (BPA) Appendix and Additional Discount Program (ADP) Appendix for newly approved drugs. Manufacturers are required to submit fully executed signature pages along with their quote information. The P&T Committee will evaluate agents for inclusion in the Uniform Formulary and may recommend special reimbursement methods, preferential status (Tier 1), or complete exclusion from the TRICARE pharmacy benefit. Prior Authorization may apply, and agents with unsubmitted or unselected RFQs may be designated non-step preferred.

The document outlines the Department of Defense (DOD) Uniform Formulary Class for "ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS," specifically focusing on "SELECTIVE SEROTONIN REUPTAKE INHIBITORS." It details the process for drug inclusion and pricing within the DOD healthcare system, with a P&T Committee Meeting scheduled for November 5-6, 2025, and quotes due by October 27, 2025.The file specifies conditions for both Uniform Formulary (UF)/Tier 2 and Non-Formulary (NF)/Tier 3 After Step candidacy, based on submitted cost per 30-day supply. It also discusses the potential for prior authorization (PA) and step therapy requirements, where new users must first try a step-preferred agent. Manufacturers are advised to submit fully executed signature pages along with quote information. Additionally, the document addresses TRICARE Retail Refund calculations, including details on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts, which are crucial for determining total calculated refunds.

The document outlines the Department of Defense (DOD) Uniform Formulary's P&T Committee Meeting scheduled for November 5-6, 2025, with quotes due by October 27, 2025. The focus is on "Antidepressants and Non-Opioid Pain Syndrome Agents." It includes appendices for Blanket Purchase Agreements and Additional Discount Programs for newly approved drugs within this class. Manufacturers are required to submit executed signature pages with their quote information. The document details formulary notes, including potential prior authorization requirements, special reimbursement methods, and the possibility of designating certain agents as Tier 1 or excluding them from TRICARE. Step therapy guidelines are also outlined, requiring new users to try step-preferred agents before non-step-preferred ones. The pricing per unit will be consistent across all package sizes and dispensing venues for Blanket Purchase Agreements, while Additional Discount Programs detail refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts.

The Department of Defense (DOD) Uniform Formulary Class for Oncological Agents outlines procedures for the upcoming P&T Committee Meeting on November 5-6, 2025, with quotes due by October 27, 2025. This document, comprising Blanket Purchase Agreement Appendices and Additional Discount Program Appendices for Newly Approved Drugs, details requirements for drug manufacturers. It specifies that agents will be reviewed for formulary inclusion, potential prior authorization, special reimbursement methods, and possible exclusion from the TRICARE pharmacy benefit program. Manufacturers must submit fully executed signature pages and quote information, with a clear instruction not to submit a quote if a cell is highlighted red. The document also addresses pricing, including price per unit for various package sizes, and outlines refund calculations for TRICARE retail refunds based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts. Agents with unsubmitted or unselected Request for Quotation (RFQ) may be designated non-step preferred (after-step).

The Department of Defense (DoD) Uniform Formulary is reviewing "ALZHEIMERS AGENTS" for potential inclusion or changes in formulary status. Quotes for these agents are due by October 27, 2025, with the P&T Committee Meeting scheduled for November 5-6, 2025. Manufacturers are reminded to submit fully executed signature pages along with their quote information. The review process may lead to prior authorization requirements, special reimbursement methods, or even complete exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected may be designated as non-step preferred. Pricing for Blanket Purchase Agreements will be consistent across package sizes for a given dosage form and strength. Additionally, the file outlines details for an Additional Discount Program, including TRICARE Retail Refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) where applicable.

This document outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Program for Oncological Agents, specifically for Chronic Myelogenous Leukemia. Quotes for these agents are due by October 27, 2025, in anticipation of the P&T Committee Meeting on November 5-6, 2025. The document details requirements for submitting quotes for both Uniform Formulary and Non-Formulary drugs, emphasizing that "NO QUOTE" should be explicitly stated if no submission is intended. It also covers the TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs, including calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts. Prior authorization may apply, and the committee may recommend preferential status or exclusion from the TRICARE pharmacy benefit. Manufacturers must submit fully executed signature pages with their quote information.

The document outlines requirements for the Department of Defense (DOD) Uniform Formulary Class: TARGETED IMMUNOMODULATORY BIOLOGICS, specifically for the INTERLEUKIN 23 subclass. It details procedures for Blanket Purchase Agreements (BPAs) and an Additional Discount Program for newly approved drugs. Key dates include a P&T Committee Meeting on November 5-6, 2025, and a quote due date of October 27, 2025. The file emphasizes prior authorization, step therapy, and potential preferential status for high-value products or exclusion for low-value ones. Manufacturers are required to submit executed signature pages with quotes, noting that non-submitted or non-selected agents may be designated as non-step preferred. It also details TRICARE Retail Refund calculations based on Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) for different formulary scenarios.

This government file outlines the Department of Defense (DOD) Uniform Formulary and Additional Discount Program for the ALCOHOL DETERRANTS-NARCOTIC ANTAGONISTS class, specifically NARCOTIC ANTAGONISTS. It details a review by the P&T Committee on November 5-6, 2025, with quotes due by October 27, 2025. The document includes multiple appendices for newly approved drugs under both Blanket Purchase Agreements and Additional Discount Programs, consistently indicating "NO QUOTE" for listed NDC numbers under Scenario 1 for Uniform and Non-Formulary categories. Key notes emphasize that agents will be reviewed per 32 CFR 199.21(g)(5), with potential for Prior Authorization (PA), special reimbursement methods, preferential status, or complete exclusion from TRICARE. Manufacturers are reminded to submit fully executed signature pages with their quotes. The file also addresses pricing consistency across package sizes and the calculation of TRICARE Retail Refunds, including Federal Ceiling Price (FCP) and Wholesale Acquisition Cost (WAC) discounts.

The Department of Defense (DOD) Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) for pharmaceutical agents to be included on the Uniform Formulary (UF). This RFQ allows manufacturers to submit offers to reduce DOD costs for agents under consideration by the Pharmacy and Therapeutics (P&T) Committee. The process involves submitting quotes for UF Blanket Purchase Agreements (UF BPA) for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), and UF Additional Discount Program (UF ADP) agreements for the TRICARE retail network. The P&T Committee evaluates pharmaceutical agents based on clinical effectiveness and cost-effectiveness to determine their placement on the UF and their cost-share tier classification (generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary). Manufacturers must provide specific information, including NDC Price Lists and responses to clinical questions. The RFQ outlines submission procedures, deadlines, and criteria for evaluating quotes, emphasizing adherence to legal and regulatory requirements.